| 產(chǎn)品名稱 | Exemestane - Aromasin | FCE 24304 |
| 產(chǎn)品貨號 | Axon 2045 CAS [107868-30-4] MF C20H24O2MW 296.40 Purity: 98% Optical purity: Optically pure Soluble in DMSO and Ethanol Description Orally active, irreversible steroidal aromatase inhibitor (IC50 = 20 nM). Destabilizes aromatase and lowers estrogen levels; breast cancer therapy. References Certificates Categories Extra info D Giudici et al. 6-Methylenandrosta-1,4-diene-3,17-dione (FCE 24304): A new irreversible aromatase inhibitor. J. Steroid Biochem. 1988, 30 (1–6), ?391–394. ? N Mauras et al. Pharmacokinetics and Dose Finding of a Potent Aromatase Inhibitor, Aromasin (Exemestane), in Young Males. J. Clin. Endocrinol. Metab. 2003, 88(12), 5951–5956.? ? RC Coombes et al. A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer. N. Engl. J. Med. 2004, 350, 1081-1092.? Certificate of Analysis Material Safety Data Sheet Cell Signaling & Oncology Endocrinology EC 1.14.14.1 Cytochrome P450 Pfizer Licensed Products Irreversible steroidal aromatase (CYP19A1) inhibitor Chemical name (8R,9S,10R,13S,14S)-10,13-dimethyl-6-methylene-7,8,9,10,11,12,13,14,15,16-decahydro-3H-cyclopenta[a]phenanthrene-3,17(6H)-dione Source information Pfizer compound; Sold for research purposes under agreement from Pfizer Inc. Parent CAS No. [107868-30-4] Order Size Unit Price Stock 10 mg €80.00 In Stock |
| 產(chǎn)品價格 | 現(xiàn)貨詢價，電話：010-67529703 |
| 產(chǎn)品規(guī)格 | |
| 產(chǎn)品品牌 | axonmedchem |
| 產(chǎn)品概述 | |
| 產(chǎn)品詳情 |
Exemestane - Aromasin | FCE 24304Axon 2045 CAS [107868-30-4] MF C20H24O2
Description
Orally active, irreversible steroidal aromatase inhibitor (IC50 = 20 nM). Destabilizes aromatase and lowers estrogen levels; breast cancer therapy.
Irreversible steroidal aromatase (CYP19A1) inhibitor
Chemical name(8R,9S,10R,13S,14S)-10,13-dimethyl-6-methylene-7,8,9,10,11,12,13,14,15,16-decahydro-3H-cyclopenta[a]phenanthrene-3,17(6H)-dione Source informationPfizer compound; Sold for research purposes under agreement from Pfizer Inc.Parent CAS No.[107868-30-4] |
| 產(chǎn)品資料 |
